Literature DB >> 22547711

Response from Dr. Cleveland and colleagues.

.   

Abstract

Mesh：

Year:  2012        PMID： 22547711      PMCID： PMC4612513          DOI： 10.14219/jada.archive.2012.0194

Source DB:  PubMed          Journal:  J Am Dent Assoc        ISSN： 0002-8177            Impact factor:   3.634


× No keyword cloud information.
  6 in total

1.  FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

2.  FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

3.  Oral and oropharyngeal cancer: what are the next steps?

Authors:  Michael Glick; Newell W Johnson
Journal:  J Am Dent Assoc       Date:  2011-08       Impact factor: 3.634

4.  The epidemiology of oral HPV infection among a multinational sample of healthy men.

Authors:  Aimee R Kreimer; Alessandro Villa; Alan G Nyitray; Martha Abrahamsen; Mary Papenfuss; Danelle Smith; Allan Hildesheim; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-12-10       Impact factor: 4.254

5.  Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers.

Authors:  Elaine M Smith; Linda M Rubenstein; Thomas H Haugen; Eva Hamsikova; Lubomir P Turek
Journal:  Cancer Causes Control       Date:  2010-04-17       Impact factor: 2.506

6.  Oral sexual behaviors associated with prevalent oral human papillomavirus infection.

Authors:  Gypsyamber D'Souza; Yuri Agrawal; Jane Halpern; Sacared Bodison; Maura L Gillison
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.